Skip to content
Inciteful Med

Building Your Care Team & First Visit Prep

Last updated:

Managing Fabry disease requires a multidisciplinary care team, typically led by a geneticist. To get the best care, gather your genetic reports, lab tests, and a family health history before your first visit, and look for specialists who regularly treat this rare condition.

Key Takeaways

  • • Fabry disease affects multiple organs and requires a coordinated, multidisciplinary care team (MDT).
  • • Your core medical team should be led by a geneticist and include specialists for your kidneys, heart, nervous system, and eyes.
  • • Bring your genetic report, lab results, baseline imaging, and a family health tree to your first specialist appointment.
  • • Interview your doctors to ensure they have experience with Fabry disease and participate in formal registries or specialized Fabry Centers.

Because Fabry disease affects so many different organs, it is impossible for one doctor to manage it alone. “Hiring” the right care team is one of the most important steps you will take to protect your long-term health. You are looking for a multidisciplinary team (MDT)—a group of specialists who talk to each other and follow a coordinated plan [1][2].

Your Care Team Roster

A complete Fabry care team should include the following specialists, ideally led by a “quarterback” (usually a Geneticist or a Metabolic Specialist) [1][3]:

  • Geneticist / Genetic Counselor: They confirm your diagnosis, explain your specific mutation, and help you create a pedigree (family tree) to identify other relatives who may be at risk [1][4].
  • Nephrologist (Kidney Specialist): They monitor your kidney function (eGFR) and check for protein in your urine (proteinuria), which are critical early signs of Fabry progression [1][5].
  • Cardiologist (Heart Specialist): They use advanced tools like Cardiac MRI (CMR) and T1 mapping to look for early heart thickening or scarring [6][7].
  • Neurologist: They manage neuropathic pain (burning in hands/feet) and monitor for any early signs of stroke [1][8].
  • Ophthalmologist (Eye Specialist): They check for cornea verticillata (a whorl-like pattern in the eye) that is a classic hallmark of Fabry [9][3].
  • Otolaryngologist (ENT): They monitor for hearing loss or vertigo, which can be early symptoms [10][3].
  • Pediatrician: If the patient is a child, a pediatrician with experience in rare diseases is essential for monitoring growth and development [1][11].

Preparing for Your First Visit

Specialists in rare diseases often have long wait times. To make the most of your first appointment, you should bring the following “physical artifacts” [11][12]:

  1. The Genetic Report: This is the most important document. It lists your specific GLA gene mutation [13][14].
  2. Laboratory Results: Copies of your alpha-galactosidase A enzyme activity levels and your Lyso-Gb3 levels [15][16].
  3. Family Pedigree: A multi-generational family tree showing any relatives with history of kidney failure, heart issues, or early stroke [3][12].
  4. Baseline Imaging: If you have already had an echocardiogram (heart ultrasound) or an MRI, bring the actual images on a disc or via a digital portal, not just the written report [17][18].
  5. Symptom Diary: A clear list of when symptoms (like pain crises, stomach issues, or lack of sweating) first started and what triggers them [11][19].

Because the sheer volume of information provided by a multidisciplinary team can be overwhelming, bring a family member or friend to take notes for you.

Vetting Your Specialist

Because Fabry is rare, many doctors may have never seen a case before. It is okay to “interview” your doctor to ensure they have the expertise you need [20][21].

  • Ask about their MDT: Do they have a formal system for talking to your other specialists? If they don’t, you may end up overwhelmed by conflicting advice [2].
  • Ask about “Fabry Centers”: Does the clinic follow the established consensus guidelines for Fabry management? In many cases, it is worth traveling to a “Fabry Excellence Center” for your annual staging even if your day-to-day care is local [20][22].
  • Ask about Registries: Does the clinic participate in international Fabry registries? This is a sign that the team is active in the latest research and stays up-to-date on new treatments [23][7].

Frequently Asked Questions

Which doctors should be on my Fabry disease care team?
Because Fabry disease affects multiple organ systems, your care should be managed by a multidisciplinary team. This group is typically led by a geneticist or metabolic specialist and should include a nephrologist, cardiologist, neurologist, ophthalmologist, and an ENT.
What documents should I bring to my first Fabry disease appointment?
You should bring your genetic report showing your specific GLA mutation, recent lab results including alpha-galactosidase A and Lyso-Gb3 levels, a detailed family health tree, any baseline imaging like a cardiac MRI, and a symptom diary.
How do I know if my specialist is experienced with Fabry disease?
Because the condition is rare, it is important to ask your doctor how many Fabry patients they currently treat. You should also ask if they follow established consensus guidelines, work within a multidisciplinary team, and participate in international Fabry registries.
Why is it recommended to visit a Fabry Excellence Center?
A positive STAT6 result means the protein was found in the cell nucleus, which is the hallmark diagnostic marker for solitary fibrous tumor. This test distinguishes SFT from other tumors that may look similar under the microscope.
Why is it recommended to visit a Fabry Excellence Center?
Fabry Centers have dedicated teams that specialize in this rare condition and stay up-to-date on the latest research and clinical trials. Even if you receive your day-to-day care locally, visiting a specialized center annually helps ensure your treatment plan is comprehensive and accurate.

Questions for Your Doctor

  • • How many patients with Fabry disease are currently under your care, and how many of them have my specific GLA mutation?
  • • Do you have a formal multidisciplinary team (MDT) or a regular 'case board' where you coordinate my care with my cardiologist and nephrologist?
  • • What is your protocol for using advanced imaging, such as Cardiac MRI with T1 mapping or strain analysis, to monitor my heart for early damage?
  • • If I am female: How do you interpret my enzyme and Lyso-Gb3 levels in light of X-chromosome inactivation (Lyonization)?
  • • Does your clinic participate in any national or international Fabry disease registries or clinical trials?

Questions for You

  • • What specific symptoms (like burning pain, stomach issues, or lack of sweating) have I or my child been experiencing, and when did they first start?
  • • Are there any relatives in my family tree who had 'early' heart failure, unexplained kidney disease, or strokes?
  • • Am I comfortable with the level of coordination between my current doctors, or do I feel like I am the one doing all the 'middleman' work?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    [Heart involvement in Anderson-Fabry disease: Italian recommendations for diagnostic, follow-up and therapeutic management].

    Pieruzzi F, Pieroni M, Zachara E, et al.

    Giornale italiano di cardiologia (2006) 2015; (16(11)):630-8 doi:10.1714/2066.22434.

    PMID: 26571477
  2. 2

    Multidisciplinary Care Model as a Center of Excellence for Fabry Disease: A Practical Guide to Diagnosis and Management by Clinical Specialty in South Korea.

    Lee SY, Kim IY, Ahn SH, et al.

    Journal of clinical medicine 2025; (14(13)) doi:10.3390/jcm14134400.

    PMID: 40648776
  3. 3

    [Fabry disease].

    Stephan F, Haber R

    Annales de dermatologie et de venereologie 2017; (144(2)):137-146 doi:10.1016/j.annder.2016.10.010.

    PMID: 28104284
  4. 4

    The unlikely combination: Anderson-Fabry disease and congenital dyserythropoietic anemia type II in a pediatric patient.

    Elsherif Y, Ibrahim IA, Elsherif O, Abukhadijah HJ

    Clinical case reports 2024; (12(10)):e9354 doi:10.1002/ccr3.9354.

    PMID: 39386347
  5. 5

    Enzyme replacement therapy for Anderson-Fabry disease.

    El Dib R, Gomaa H, Carvalho RP, et al.

    The Cochrane database of systematic reviews 2016; (7()):CD006663 doi:10.1002/14651858.CD006663.pub4.

    PMID: 27454104
  6. 6

    Fabry disease cardiomyopathy: A state-of-the-art review.

    Pande S, Varzideh F, Gambardella J, et al.

    Progress in cardiovascular diseases 2025; (92()):43-65 doi:10.1016/j.pcad.2025.08.003.

    PMID: 40840785
  7. 7

    Left atrial strain correlates with severity of cardiac involvement in Anderson-Fabry disease.

    Halfmann MC, Altmann S, Schoepf UJ, et al.

    European radiology 2023; (33(3)):2039-2051 doi:10.1007/s00330-022-09183-7.

    PMID: 36322192
  8. 8

    Molecular Pathogenesis of Central and Peripheral Nervous System Complications in Anderson-Fabry Disease.

    Tuttolomondo A, Baglio I, Riolo R, et al.

    International journal of molecular sciences 2023; (25(1)) doi:10.3390/ijms25010061.

    PMID: 38203231
  9. 9

    Fabry disease due to G171S GLA mutation: An atypical small nerve fiber sparing variant?

    Prencipe M, Posarelli C, Figus M, Gabbriellini G

    European journal of ophthalmology 2021; (31(6)):NP53-NP57 doi:10.1177/1120672120939496.

    PMID: 32586128
  10. 10

    Cochleovestibular Signs As the First Manifestation of Fabry Disease: A Case Report and Literature Review.

    Zakaria Y, Yahya N, Kissani N

    Cureus 2024; (16(3)):e57289 doi:10.7759/cureus.57289.

    PMID: 38690505
  11. 11

    [A case of Anderson-Fabry disease: a multidisciplinary approach for diagnosis and follow up].

    Zito A, De Pascalis A, Armeni A, et al.

    Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 2018; (35(5)).

    PMID: 30234233
  12. 12

    The importance of a multidisciplinary approach in two tricky cases: the perfect match for Fabry disease.

    Berti GM, Aiello V, Vischini G, et al.

    BMC nephrology 2025; (26(1)):77 doi:10.1186/s12882-025-04009-2.

    PMID: 39948544
  13. 13

    Treatment of Anderson-Fabry Disease.

    Simonetta I, Tuttolomondo A, Daidone M, et al.

    Current pharmaceutical design 2020; (26(40)):5089-5099 doi:10.2174/1381612826666200317142412.

    PMID: 32183665
  14. 14

    Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype.

    Choi JH, Lee BH, Heo SH, et al.

    Medicine 2017; (96(29)):e7387 doi:10.1097/MD.0000000000007387.

    PMID: 28723748
  15. 15

    Identification of Four New Mutations in the GLA Gene Associated with Anderson-Fabry Disease.

    Anania M, Pieruzzi F, Giacalone I, et al.

    International journal of molecular sciences 2025; (26(2)) doi:10.3390/ijms26020473.

    PMID: 39859188
  16. 16

    [The neurological manifestations of Fabry disease. A review].

    Firsov KV, Kotov AS

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2016; (116(9)):98-105 doi:10.17116/jnevro20161169198-105.

    PMID: 27735906
  17. 17

    Cardiac involvement in Anderson-Fabry disease. The role of advanced echocardiography.

    Spinelli L, Bianco A, Riccio E, et al.

    Frontiers in cardiovascular medicine 2024; (11()):1440636 doi:10.3389/fcvm.2024.1440636.

    PMID: 39314767
  18. 18

    Atypical Distribution of Late Gadolinium Enhancement of the Left Ventricle on Cardiac Magnetic Resonance in Classical Anderson-Fabry Disease.

    Kasuya S, Suzuki M, Inaoka T, et al.

    Journal of the Belgian Society of Radiology 2016; (100(1)):6 doi:10.5334/jbr-btr.906.

    PMID: 30151436
  19. 19

    New mutation in Fabry disease: c.448delG, first phenotypic description.

    Calabrese E, Rodriguez Botta G, Rosenfeld DP

    Molecular genetics and metabolism reports 2021; (27()):100708 doi:10.1016/j.ymgmr.2021.100708.

    PMID: 33732617
  20. 20

    [The nephropathy in the Anderson-Fabry disease: new recommendations for the diagnosis, the follow-up and the therapy].

    Mignani R, Gallieni M, Feriozzi S, et al.

    Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 2015; (32(4)).

    PMID: 26252265
  21. 21

    Diagnosis, treatment, and follow-up of Fabry disease in pediatrics.

    Cárdenas-Aguilera JG, Chacón-Acevedo KR, Zarante-Bahamón AM, et al.

    Molecular genetics and metabolism 2026; (147(3)):109709 doi:10.1016/j.ymgme.2025.109709.

    PMID: 41519064
  22. 22

    Anderson-Fabry Disease: From Endothelial Dysfunction to Emerging Therapies.

    Stamerra CA, Del Pinto R, di Giosia P, et al.

    Advances in pharmacological and pharmaceutical sciences 2021; (2021()):5548445 doi:10.1155/2021/5548445.

    PMID: 34095851
  23. 23

    [State of the art and projects of the Italian Fabry Disease Cardiovascular Registry].

    Biagini E, Limongelli G, Parisi V, et al.

    Giornale italiano di cardiologia (2006) 2025; (26(9)):666-676 doi:10.1714/4542.45431.

    PMID: 40864485

This page provides educational information on building a care team for Fabry disease. It does not replace professional medical advice, so always consult your healthcare provider to design a care plan tailored to your specific medical needs.

Stay up to date

Get notified when new research about Fabry disease is published.

No spam. Unsubscribe anytime.